A Phase II Multicenter, Randomized, Double-blind, Parallel, Placebo-controlled Trial to Evaluate the Efficacy and Safety of IBI112 in Different Dose Regimens for the Treatment of Subjects With Moderate-to-severe Plaque Psoriasis
Latest Information Update: 31 Jan 2024
At a glance
- Drugs Picankibart (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Sponsors Innovent Biologics
- 16 Feb 2023 Status changed to completed , according to an Innovent Biologics media release.
- 15 Sep 2022 Planned End Date changed from 31 Jan 2023 to 1 Sep 2023.
- 09 Aug 2022 According to Innovent Biologics media release, the study period is 52 weeks (one year), and currently, subjects in the placebo group have been treated with IBI112, and the dosing and follow-up of the study are ongoing